Combination therapy of anti-OX40, anti-4-1BB, anti-PD-L1, docetaxel, and adenovirus-based tumor antigen vaccine was shown to induce CD4+/CD8+ T cell proliferation and activity, overcome CD4+ and CD8+ T cell exhaustion, and delay tumor growth in both T cell–inflamed and non-T cell–inflamed murine tumor models (64). The gene discussed is TNFRSF9; the disease is neoplasm.